EQS-News: Linde Announces First Quarter 2025 Earnings and Conference Call Schedule

EQS-News: Linde plc / Key word(s): Quarter Results Linde Announces First Quarter 2025 Earnings and Conference Call Schedule 03.04.2025 / 12:00 CET/CEST The issuer is solely responsible for the content of this announcement. Linde Announces First Quarter 2025 Earnings and Conference Call Schedule Woking, UK, April 3, 2025 – Linde (Nasdaq: LIN) will release its first quarter 2025 financial results by 06:00 EDT/midday CEST on Thursday, May 1, 2025. The Company will host and webcast its conference call at 09:00 EDT/15:00 CEST, which will be available to the public and the med...

EQS-News: Linde Increases Dividend 8%

EQS-News: Linde plc / Key word(s): Dividend Linde Increases Dividend 8% 25.02.2025 / 18:05 CET/CEST The issuer is solely responsible for the content of this announcement. Linde Increases Dividend 8% Woking, UK, February 25, 2025 – Linde plc (Nasdaq: LIN) today announced its Board of Directors has declared an 8% increase in the company's quarterly dividend to $1.50 per share. This marks the 32nd consecutive year of quarterly dividend increases on the company’s common stock. The dividend is payable on March 27, 2025, to shareholders of record on March 13, 2025.   About...

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/07/2025

Cellectis : Cellectis: the reference player in allogeneic CAR-T cells

Cellectis is the French specialist in allogeneic CAR-T cells, now mainly developed in cancer treatment. Its first CAR-T in partnership with Servier and Allogene is currently in the pivot phase in first-line diffuse B-cell lymphoma, while its most advanced own CAR-T candidate is expected to enter into the pivot phase II in H2 this year in acute lymphoblastic leukaemia. Bolstered by a recent deal with AstraZeneca, which acquired a stake in the company (+44%), we are initiating coverage of the stock with an Outperform rating and target price of € 6.5 (+480%).

Cellectis : Cellectis : l’acteur de référence des CAR-T allogéniques

Cellectis est le spécialiste français des CAR-T allogéniques, développés aujourd’hui essentiellement dans le traitement des cancers. Son premier CAR-T partenarisé à Servier et Allogene est actuellement en phase pivot en 1ere L du lymphome diffus à cellules B alors que son candidat CAR-T propre le plus avancé devrait entrer en phase 2 pivot au S2 de cette année en Leucémie Lymphoïde Aigue. Fort d’un accord récent avec AstraZeneca qui a pris une participation dans la société (44%), nous initions la couverture du titre avec une recommandation à Surperformance et un OC de 6.5 € (+480%).

Prysmian : 2028 roadmap and potential hybrid bond issuance

On March 26, Prysmian held a CMD to update investors less than two years after its last CMD as the company has already surpassed the targets set back then. Looking into the roadmap set for 2028, both the Transmission and the Digital Solutions segments are expected to be the main growth drivers. We believe that the targets set for 2028 are achievable amid good organic growth and continued bolt-on M&A. We expect net leverage to continue to decrease y/y supported by the strong FCF generation and expected limited M&A before 2027 as the company focuses on the recently acquired Encore Wire and Chann...